cyrilzakka/clinical-trials huggingface dataset:
Effect of Ballet Course on Lower Limb Strength, Balance, Working Memory and the Compliance and Satisfaction

In recent years, sports have become popular, and major gyms or private exercise studios have been opened continuously. A dazzling array of course content allows students to choose according to their preferences. Therefore, how to improve students' compliance with gyms or classrooms, and increase exercise frequency to develop exercise habits , is the current problem faced by the industry.

However, in the case of limited time, the academic side is looking for more effective training courses, and the industry side is trying a variety of courses that are more attractive to the public, hoping to be different from the previous types of sports, improve the motivation of public sports, increase the frequency of exercise and then Maintain exercise habits.

Compared with aerobic dance, boxing, yoga and Pilates, ballet is a niche course, but more and more studies have pointed out that ballet can effectively improve posture, improve lower limb muscle strength, and improve cognitive, executive memory, and working memory.

Therefore, this study intends to explore the effect of ballet courses on lower limb explosiveness, static balance, dynamic balance, cognitive executive function and working memory of exercise studio students. degree and become one of the courses chosen by students for their classes.


Eligibility Criteria:
Inclusion Criteria:

* Studio students willing to participate in the two-stage test.
* Aged between 20 and 64 years old.
* Able to perform test-related movements, including vertical jumping and tiptoe movements.
* No lower extremity musculoskeletal surgery has been performed within six months.

Exclusion Criteria:

* Those who are sick and unable to exercise vigorously under medical advice.
* Those who have studied classical ballet for up to one year.
The Use of Selenium to Treat Secondary Lymphedema - Breast Cancer

The primary objective of this study to assess the effectiveness of selenium compared to placebo in reducing the lymphedema in-patients with breast cancer. Secondary objectives are to assess the impact of selenium on patient's quality of life and to assess the incidence of adverse effects of selenium therapy.


Eligibility Criteria:
Inclusion Criteria:

* patients with clinically documented lymphedema of upper limb secondary to breast cancer management (surgery - axillary nodal dissection, and radiotherapy)
* patients who have had other modalities of management can be included, e.g. physical therapy, pharmacological therapy
* ECOG performance 0-2
* informed consent

Exclusion Criteria:

* active cellulitis/skin infection of the limb
* venous thrombosis of the upper limbs
* active malignancy
* any other medical condition or congenital or traumatic injury involving either limb
* patients already on selenium medication
* patients participating in another clinical study related to lymphedema
Immediate Effect of Ultrasound Therapy on Bilateral Masseter Myalgia: Randomized Single Blinded Investigational Trial

Introduction. Temporomandibular disorders (TMD) are a group of conditions that are multifactorial in nature, and it primarily presents with symptoms of pain and decreased functional capacity. Therapeutic ultrasound is a method of physical therapy that has shown clinically to provide immediate relief of pain in patients with different musculoskeletal disorders. In this study, for the purpose of immediate management of painful masticatory muscle and tissues, the investigators attempt to understand the mechanism of therapeutic ultrasound by exploring the physiologic changes peripherally and centrally. In addition, the investigators aim to determine if there is a dose response relationship between two different intensities (0.4 W/cm2 and 0.8 W/cm2) and between two sets of duty cycles (50% and 100%). A third purpose is to determine if therapeutic ultrasound applied to the masseter muscle is capable of eliciting segmental effects in the temporalis muscle. Methods. A total of 28 adult females with bilateral myalgia according to Diagnostic criteria for TMD (DC/TMD) will be recruited for this investigational trial. Each subject will be randomly allocated to one of the four ultrasound intervention groups each of which has different settings. Using Sonicator®740, therapeutic ultrasound intervention will be performed on both masseters for five minutes on each side of the face. A template will be used to confine the borders of the muscle and to determine the sites for the repeated outcome measures. Outcome parameters of: self-reported pain scale, pressure pain threshold, electromyographic muscle amplitudes and intraoral muscle temperatures will be measured for masseter and temporalis muscles on each side of the face, and will be assessed at baseline and after intervention on each side.

The "Brief Summary" above encompasses the detailed description.

Eligibility Criteria:
Inclusion Criteria:

* Adult females who have bilateral myalgia based on Diagnostic Criteria for TMD (DC-TMD) criteria and current pain intensity (≥4 out of 10, where 0 is no pain and 10 is the worst pain ever) on both sides.

Exclusion Criteria:

* Those who have a history or were diagnosed with systemic musculoskeletal disorders or rheumatologic diseases (e.g. fibromyalgia, muscular atrophy).
* Certain conditions such as neoplasms or fractures.
* Neuropathies or neurological disorders.
* Participants who are currently taking muscle relaxants or analgesics.
* Those who have undergone any form of physical therapy within the last 60 days.
Exploring Patient Reported Outcomes in Inherited Ichthyosis

The goal of this observational study is to learn about the presence of extracutaneous manifestations in patients with congenital ichthyosis.

The main question it aims to answer is:

- Do patients with congenital ichthyosis experience extracutaneous manifestations?

Participants will fill in questionnaires in which the investigators will explore whether patients experience extracutaneous manifestations, and if so what these manifestations entail. Examples of such questions are whether patients experience (joint) pain or whether they experience hindrance due to their complaints.

There is only limited knowledge about extracutaneous manifestations in patients with congenital ichthyosis. With this study, the investigators aim to identify extracutaneous manifestations with questionaires based on patient reported outcomes.

Secondary research questions include:

* What is the prevalence of joint complaints in patients with congenital ichthyosis
* What is the influence of ichthyosis on the quality of life patients experience

Furthermore, the investigators aim to discover knowledge gaps in current patient management and possible areas of improvement in patient care towards healthcare professionals.

Eligibility Criteria:
Inclusion Criteria:

* 16 years and older
* Clinically and genetically confirmed congenital ichthyosis

Exclusion Criteria:

* \<16 years of age
* Not able to read Dutch
* Not able to fill in questionnaires online or in print
Assessment of Marginal and Internal Fit of High Performance Polymer PEEK Endocrown Using Two Preparation Designs

First, Participants in this study will be recruited according to inclusion criteria. Proper examination for the participants (clinically and radiographically). Preparation for endodontically treated molar for receiving high performance polymer endocrown. Checking and verification for the restoration (trying) and assessment of marginal and internal fit by replica technique. Then final cementation of endocrown.

Examination and diagnosis:

Selection and examination of the patients according to inclusion and exclusion criteria. Diagnosis of the patient's chief complaint and teeth that will be involved in this study will be done.

Primary alginate impressions for diagnosis on primary casts and for mounting. The patients will be asked to maintain good oral hygiene measures by using tooth brush twice daily.

Taking a professional pre-operative photo.

Tooth preparation procedure:

Preparation of endocrown with two preparation designs on endodontically treated molars.

After tooth preparation, the final impression will be taken for each participant using polyvinyl siloxane impression and temporization of cavity using light curable temporary material.

Restoration trial appointment:

Endocrown try in and assessment of marginal and internal fit using replica technique with light body rubber impression.

Fabrication of final restoration:

Delivery of high performance polymer endocrown will be fabricated according to the two preparation designs; butt and bevel.

Eligibility Criteria:
Inclusion Criteria:

1. Patient age range from 18 years -50 years old. They should be able to read and write so they can sign the informed consent.
2. Patient should have a good physical and psychologically state to be able to withstand the steps of the restoration procedure.
3. Have a molar with root canal filling with no active periodontal or apical involvement.
4. Patients having root canal treatment teeth indicated for endocrown treatment with 3 or 4 axial walls remaining.
5. Patient with axial wall length not less than 3 mm and not more than 5 mm.
6. Patient should have good oral hygiene and motivation.

Exclusion Criteria:

1. Patient with periodontal or apical involvement or improper root canal treatment.
2. Severe loss of the tooth structure in which the amount of the remaining tooth structure is less than 2mm.
3. Patient with poor oral hygiene or with occlusal instability
4. Patient with improper physical or psychological state.
5. Patient not pregnant or lactating.
Long-term of Remote Ischemic Preconditioning in Patients With Mild Hypertension

According to the latest survey data of China hypertension annual meeting, there are about 300 million patients with hypertension in China, with 10 million new cases of hypertension each year, and there is an obvious trend of younger people. In particular, young and middle-aged people are in a state of mild hypertension for a long time, which causes great pressure on health and medical treatment. At present, the main clinical measures for mild hypertension are to change their eating habits, quit smoking and alcohol, exercise and other lifestyle changes, as well as drug control. For most patients with mild hypertension, drug control is not the best choice. It has been reported that remote ischemic preconditioning (RIPC) may play an effective role in reducing blood pressure .The purpose of this study was to investigate the extent of long-term application of RIPC to reduce blood pressure in patients with mild hypertension.

A total of 200 patients with mild hypertension were enrolled in this study, using the method of open label and parallel grouping; 100 cases in the experimental group and 100 cases in the control group, The experimental group was divided into life intervention + drug group and life intervention + ripc group, with 50 patients in each group. The results of 24-hour ambulatory blood pressure monitoring (ABPM) of the three groups were observed before and 3 months after use, including HR, pulse pressure, 24-hour systolic blood pressure, 24-hour diastolic blood pressure, daytime systolic blood pressure, daytime diastolic blood pressure, nighttime systolic blood pressure and nighttime diastolic blood pressure. The changes of renalase, catecholamine, renin, angiotensin - Ⅱ, aldosterone, RhoA kinase, no, adenosine and bradykinin were observed.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed patients with mild hypertension (SBP: 140\~159mmHg; DBP: 90\~99mmHg)

Exclusion Criteria:

* Cannot tolerate RIPC
* Non-essential hypertension
* patients who have uncontrolled severe arrhythmia, diabetes, electrolyte disturbance
* patients who have severe organic diseases such acute myocardial infarction, cardiac insufficiency, abnormal renal function, etc.
Bacterial Biofilms in Reconstructive Breast Prostheses Following Mastectomy

Breast implants, either cosmetic or reconstructive, are among the most common procedures performed by plastic surgeons. Bacterial infections or biofilms are implicated in the majority of breast implant complications including infection requiring explantation, capsular contracture (CC), and/or breast-implant associated anaplastic large cell lymphoma (BIA-ALCL). The research team, which has already extensively characterized bacterial pathogenesis in the urinary tract and designed non-antibiotic therapeutics to reduce the incidence of catheter-associated urinary tract infections (CAUTIs), and proposal will study bacteria-breast implant interactions and explore further the impact of the breast microbiome. The proposed research provides a greater understanding of which bacteria can colonize breast implants, their source, and how effective antibiotic pocket irrigation is at eliminating them, and begins to examine the mechanisms by which bacteria bind and colonize the implant surface. These insights will set the groundwork for developing new therapeutic agents that can disrupt the binding of certain bacteria to breast implants. Strategies that minimize problems bacteria can cause, while avoiding antibiotics, will reduce bacteria-related implant complications, limit antibiotic-related side effects, and reduce bacterial resistance.


Eligibility Criteria:
Inclusion Criteria:

* Female
* Between 18 and 75 years of age, inclusive
* Undergoing bilateral mastectomy reconstruction with tissue expanders (ipsilateral therapeutic/contralateral prophylactic) planned to be exchanged for breast implants
* Able to understand and willing to sign an IRB-approved written informed consent document

Exclusion Criteria:

* Male
Sensory Optimization of the Hospital Environment

The long-term goal of this project is to improve the health and well-being of preterm infants and their parents. Although there is evidence to support positive multisensory interventions in the NICU, these interventions are often applied in an inconsistent manner, reducing their benefit. Through a rigorous and scientific process, we have developed a structured multisensory intervention program, titled Supporting and Enhancing NICU Sensory Experiences (SENSE), which includes specific doses and targeted timing of evidence-based interventions such as massage, auditory exposure, rocking, holding, and skin-to-skin care. The interventions are based on the infant's developmental stage and are adapted based on the infant's medical status and behavioral cues. The multisensory interventions are designed to be conducted during each day of NICU hospitalization by the parents, who are educated and supported to provide them. The proposed work aims to determine the effect of multisensory interventions on parent mental health, parent-child interaction, brain activity (amplitude integrated electroencephalography), and infant developmental outcomes through age 2 years, with specific attention to language outcome.

Two-hundred fifteen parent-infant dyads of preterm infants born ≤ 32 weeks gestation and admitted to a Level IV NICU (and associated Level III NICU) will be enrolled within 1 week of birth. Infants will be randomized to either the SENSE multisensory program or to the standard of care during the NICU stay. The SENSE program combines structured, easy-to-conduct, multisensory interventions with parent engagement to optimize outcomes in the complex medical environment of the NICU. Standardized assessments of parent mental health, infant neurodevelopment, and parent-child interaction will be conducted prior to NICU discharge and at 6 months, 1 year, and 2 years, adjusted for prematurity. Differences between groups will be investigated. Brain activity during NICU stay, including in the presence and absence of different sensory exposures, will also be investigated. The expected outcome is that the SENSE multisensory program will have a positive effect on improving outcomes.

Eligibility Criteria:
Inclusion Criteria:

* ≤ 32 weeks estimated gestational age (EGA)
* recruited within the first week of life

Exclusion Criteria:

* \> 32 weeks EGA at birth
* \>7 days old
* become wards of the state
* have a suspected or confirmed congenital anomaly
* face a high immediate threat of death, per the opinion of the attending physician.
A Drug Interaction Study Assess the Effects of ZSP1273 Tablets on the Pharmacokinetics of Warfarin and Midazolam

This study is a single-center, open label phase I clinical study to characterize the DDIs potential of ZSP1273 With Warfarin and Midazolam in Chinese healthy participants. This study also aims to evaluate the safety and tolerability of ZSP1273 in the presence of Warfarin and Midazolam.


Eligibility Criteria:
Inclusion Criteria:

1. Adult, male and female participants, 18 to 55 years of age, inclusive, at first Check-In Visit;
2. Body mass index (BMI) ≥19 to ≤26kg/m2 and total body weight \>50 kg(male) or \>45kg(female) at Screening (calculated as a function of measured height and weight according to the formula, BMI = kg / m2 where m2 is height in meters squared);
3. Ability to understand and willingness to sign a written informed consent form;
4. Normal physical examination, vital signs, 12-lead ECG, Chest X-ray images (anteroposterior) and clinical laboratory values, or any abnormality that is non-clinically significant.

Exclusion Criteria:

1. Participants with a history of hypersensitivity to study drug(ZSP1273,warfarin, midazolam) or any component of study medication;
2. Participants with a history of and/or signs and symptoms of current abnormal hemostasis or blood dyscrasia or abnormal prothrombin time (PT), international normalized ratio (INR), or activated partial thromboplastin time at screening;
3. Smoking more than 5 cigarettes per day within 3 months prior to screening，or who cannot stop using any tobacco products during the study period;
4. Participants who donated blood/bleeding profusely (\> 400 mL) 3 months prior to randomization;
5. Those with clinically significant ECG abnormalities, or QTcF \> 450ms in men and QTcF \> 470ms in women;
6. Participants who test positive at screening for human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), Hepatitis C virus (HCV) antibody or Syphilis spirochete-specific antibodies (TPPA);
7. Participants who test positive at Screening and/or admission (Day -1) for alcohol abuse.
8. Females who are pregnant, lactating, or likely to become pregnant during the study.
9. History of dysphagia or any gastrointestinal disorder that affect absorption
Augmenting Massed Prolonged Exposure With a Stellate Ganglion Block to Treat PTSD

This is a small, open-label treatment study that tests the potential safety and treatment effectiveness of a stellate ganglion block combined with Massed Prolonged Exposure (PE). Each of the 12 participants will receive ten 90-minute sessions of Massed Prolonged Exposure and an injection of a stellate ganglion block between the first and second PE sessions.

Massed PE will be conducted by doctoral-level therapists. Participants will meet with their providers for individual, 90-minute sessions. They will then be asked to complete out-of-session treatment assignments throughout the rest of the day. Between the individual therapy session and out-of-session treatment assignments, participants will engage in approximately four to six hours of treatment per day, Monday through Friday, for two weeks. The stellate ganglion block injection will be administered between the first and second massed PE session by qualified medical personnel as per standard operating procedure for the placement of a stellate ganglion block. A research nurse will be in attendance during the procedure and for an hour recovery period following the block administration.

During PE treatment, participants will complete interim assessments of their PTSD symptoms, mood symptoms, trauma-related cognitions, and suicidal ideation proceeding sessions 6 and 10.

Eligibility Criteria:
Inclusion Criteria:

1. Active duty or retired military service member (age 18- 65 years)
2. PTSD diagnosis as assessed by Clinician-Administered Posttraumatic Stress Scale (CAPS-5)
3. Able to speak and read English (due to standardization of outcome measures)
4. Defense Enrollment Eligibility Reporting System (DEERS)-eligible to receive care at Brooke Army Medical Center for the stellate ganglion block.

Exclusion Criteria:

1. Classification as high risk for suicide
2. Current serious mental health diagnosis (e.g., bipolar or psychosis)
3. Symptoms of moderate to severe substance (to include alcohol) use within the last 30 days
4. Pregnancy (i.e. positive pregnancy test at screening) or breastfeeding
5. Current anticoagulant use
6. History of bleeding disorder
7. Infection or mass at injection site
8. Myocardial infarction within 6 months of procedure
9. Pathologic bradycardia or irregularities of heart rate or rhythm;
10. Symptomatic hypotension
11. Phrenic or laryngeal nerve palsy
12. History of glaucoma
13. Uncontrolled seizure disorder
14. History of allergy to local anesthetics
Loco/Regional Anaesthesia Evaluation in Laparoscopic Hernioplasty

Laparoscopic hernioplasty is associated with lesser postoperative pain and quick return to work. TAP block is the gold standard technique in this type of hernioplasty. Our aim is to compare TAP block with a novel local infiltration technique that uses direct laparoscopical vision.

Laparoscopic hernioplasty is associated with lesser postoperative pain and quick return to work. TAP block is the gold standard technique in this type of hernioplasty. Our aim is to compare TAP block with a novel local infiltration technique that uses direct laparoscopical vision. Patients will be randomized into two arms of intervention that will be compared by a blind analysis. Primary outcomes will be postoperative pain evaluated systematically until 30 days postoperative, and analgesic consumption.

Eligibility Criteria:
Inclusion Criteria:

* 18 years or more.
* Programmed inguinal laparoscopic hernioplasty

Exclusion Criteria:

* Allergic to medication prescribed
* Story of mesh rejection
The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure

Safety and Efficacy of DAAs (Daclatasvir+Asunaprevir) in patients with chronic hepatitis C and chronic renal failure will be assessed.


Eligibility Criteria:
Inclusion Criteria:

* HCV RNA Positive and Genotype 1b
* No history or signs or symptoms of decompensated liver disease or hepatocellular carcinoma within 6 months
* A patient who is on dialysis, or if not MDRD eGFR\<30ml/min
* HCV treatment history: HCV treatment-naive participants, defined as never having received HCV treatment with any approved or investigational drug (including vaccines); OR HCV treatment-experienced, defined as having received previous HCV treatment with any (pegylated) interferon (\[Peg\]IFN)-based drug regimen (with or without ribavirin \[RBV\] and not including a direct-acting antiviral agent \[DAA\]). Last dose in this previous HCV treatment course should have occurred at least 2 months prior to screening
* No baseline mutation NS5A polymorphism including L31F/I/M/V and Y93H

Exclusion Criteria:

* A patient who having received Daclatasvir or Asunaprevir
* Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study
* Evidence of a medical condition contributing to chronic liver disease other than HCV or seropositive for HIV
* Diagnosed or suspected hepatocellular carcinoma or other malignancies
* Any history of, or current evidence of, clinical hepatic decompensation (e.g., ascites, encephalopathy or variceal hemorrhage)
* Received solid organ or bone marrow transplant
* Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance
* Significant renal, cardiovascular, pulmonary, or neurological disease and uncontrolled diabetes or hypertension in the opinion of the investigator
* Known hypersensitivity to study drugs, metabolites, or formulation excipients
* Who has taken investigational drugs within 2 months.